Skip to content
ClinCalc Pro
Menu
Cation-exchange resin Pregnancy: UK SPC §4.6: no data are available regarding the use of polystyrene sulfonate resins in pregnancy and lactation. The administration of Calcium Resonium in pregnancy and during breast feeding is therefore not advised unless, in the opinion of the physician, the potential benefits outweigh any potential risks.

Calcium polystyrene sulfonate

Brand names: Calcium Resonium

Used in: Hyperkalaemia

Calcium polystyrene sulfonate is an oral or rectal cation-exchange resin used to treat or prevent hyperkalaemia, including in chronic kidney disease where potassium excretion is impaired.

Adult dose

Dose: Hyperkalaemia — ORAL: 15 g three or four times a day. RECTAL: 30 g resin suspended in 150 ml of water or 10% dextrose, given as a daily retention enema. The rectal route is reserved for the patient who is vomiting or who has upper gastrointestinal tract problems, including paralytic ileus; it may be used simultaneously with the oral route for more rapid initial results, or in patients with gastroparesis who take other oral medicines within 6 hours of the resin.
Route: Oral or rectal only. ORAL: each dose given as a suspension in a small amount of water or, for greater palatability, in syrup — but NOT fruit juices, which contain potassium — in the ratio of 3 to 4 ml per gram of resin. RECTAL: as a retention enema, retained if possible for at least nine hours, after which the colon should be irrigated to remove the resin. Position the patient carefully when ingesting the resin to avoid aspiration, which may lead to bronchopulmonary complications.
Frequency: Oral: three or four times a day. Rectal: once daily as a retention enema. If both routes are used initially it is probably unnecessary to continue rectal administration once the oral resin has reached the rectum.
Max: Oral 15 g four times a day — the upper end of the licensed adult range ('the usual dose is 15g three or four times a day'); rectal 30 g daily. The SPC states no separate numerical ceiling: dosing is limited biochemically — administration of the resin should be STOPPED when the serum potassium falls to 5 mmol/litre.
Source: UK SPC (eMC) for Calcium Resonium 99.934% w/w Powder for Oral/Rectal Suspension, §4.2 (https://www.medicines.org.uk/emc/product/1439/smpc). VERBATIM §4.2 QUALIFIER: 'The dosage recommendations detailed below are a guide only; the precise requirements should be decided on the basis of regular serum electrolyte determinations.' ELDERLY: no separate dose — §4.2 heads the adult section 'Adults, including the elderly'. DRUG SEPARATION (§4.2 and §4.4): calcium polystyrene sulfonate may bind orally administered medicines and decrease their gastrointestinal absorption and efficacy; co-administration should be avoided and the resin given at least 3 hours before or 3 hours after other oral medicines. For patients with gastroparesis, a 6-hour separation should be considered. SORBITOL: concomitant use of sorbitol with calcium polystyrene sulfonate is NOT recommended — gastrointestinal stenosis, intestinal ischaemia and its complications (necrosis and perforation), some fatal, have been reported with polystyrene sulfonate alone or in combination with sorbitol. Magnesium-containing laxatives should not be used. Not recommended in patients with compromised gastrointestinal motility (including immediate post-surgery or drug-induced). In the event of clinically significant constipation, treatment should be discontinued until normal bowel movement has resumed. Advise patients to seek prompt medical advice for newly developed severe abdominal pain, nausea and vomiting, stomach distension or rectal bleeding. SOURCE NOTE: §4.4 in this bundle is truncated at the source-fetch limit (it ends mid-sentence in the children/neonates paragraph) and §4.5 was not retrieved at all — verify the full interaction and warning sections before use. §4.2 itself was retrieved complete and is the basis of every figure above.

Paediatric dose

Dose: 1 g/kg/day
Route: Oral — given preferably with a drink (not a fruit squash, because of the high potassium content) or a little jam or honey. Rectal when refused by mouth, using a dose at least as great as that which would have been given orally, diluted in the same ratio as for adults (3 to 4 ml per gram of resin); following retention of the enema the colon should be irrigated to ensure adequate removal of the resin.
Frequency: Daily total, given in DIVIDED doses
Max: 1 g/kg body weight daily in divided doses is itself the label's acute-hyperkalaemia figure and the top of the stated paediatric range; no higher paediatric dose is given in §4.2
⚠ THIS IS A DAILY TOTAL, NOT A PER-DOSE FIGURE — hence unit 'g/kg/day'. Divide the calculated daily total across the day's doses. VERBATIM §4.2 (Paediatric population, oral): 'In smaller children and infants correspondingly smaller doses should be employed by using as a guide a rate of 1mEq of potassium per gram of resin as the basis for calculation. An appropriate initial dose is 1g/kg body weight daily in divided doses, in acute hyperkalaemia. Dosage may be reduced to 0.5g/kg body weight daily in divided doses for maintenance therapy.' So: ACUTE 1 g/kg/day (the value stored above), MAINTENANCE 0.5 g/kg/day, both in divided doses. 🔴 NEONATES: 'Calcium Resonium should not be given by the oral route' — this is also a §4.3 contraindication in neonates with reduced gut motility (post-operative or drug-induced). For neonates, only the rectal route is described, and 'the minimum effective dosage within the range 0.5g/kg to 1g/kg should be employed, diluted as for adults with adequate irrigation to ensure recovery of the resin.' In children and neonates particular care is needed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin; faecal impaction following rectal administration has been reported particularly in children. concentration is null because the product is a powder for oral/rectal suspension with no fixed mg/ml strength — it is reconstituted at 3 to 4 ml per gram of resin at the point of use, so no concentration figure exists in this label. Verify any under-18 dose against a children's formulary and local guidance before prescribing.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

⚠ THIS IS A DAILY TOTAL, NOT A PER-DOSE FIGURE — hence unit 'g/kg/day'. Divide the calculated daily total across the day's doses. VERBATIM §4.2 (Paediatric population, oral): 'In smaller children and infants correspondingly smaller doses should be employed by using as a guide a rate of 1mEq of potassium per gram of resin as the basis for calculation. An appropriate initial dose is 1g/kg body weight daily in divided doses, in acute hyperkalaemia. Dosage may be reduced to 0.5g/kg body weight daily in divided doses for maintenance therapy.' So: ACUTE 1 g/kg/day (the value stored above), MAINTENANCE 0.5 g/kg/day, both in divided doses. 🔴 NEONATES: 'Calcium Resonium should not be given by the oral route' — this is also a §4.3 contraindication in neonates with reduced gut motility (post-operative or drug-induced). For neonates, only the rectal route is described, and 'the minimum effective dosage within the range 0.5g/kg to 1g/kg should be employed, diluted as for adults with adequate irrigation to ensure recovery of the resin.' In children and neonates particular care is needed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin; faecal impaction following rectal administration has been reported particularly in children. concentration is null because the product is a powder for oral/rectal suspension with no fixed mg/ml strength — it is reconstituted at 3 to 4 ml per gram of resin at the point of use, so no concentration figure exists in this label. Verify any under-18 dose against a children's formulary and local guidance before prescribing.

Verify in a children's formulary

Contraindications

  • Plasma potassium levels below 5 mmol/litre
  • Conditions associated with hypercalcaemia (e.g. hyperparathyroidism, multiple myeloma, sarcoidosis or metastatic carcinoma)
  • History of hypersensitivity to polystyrene sulfonate resins
  • Obstructive bowel disease
  • Must not be given orally to neonates, and is contraindicated in neonates with reduced gut motility (post-operative or drug-induced)
  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Side effects

  • Hypokalaemia and hypercalcaemia and their related clinical manifestations — the resin's own pharmacological actions; hypomagnesaemia has also been reported
  • Hypercalcaemia reported in well dialysed patients receiving calcium resin and occasionally in patients with chronic renal failure; some patients who cannot be screened out beforehand show a sudden rise in serum calcium to high levels after therapy
  • Gastrointestinal: gastric irritation, anorexia, nausea, vomiting, constipation and occasionally diarrhoea
  • Faecal impaction following rectal administration (particularly in children) and gastrointestinal concretions (bezoars) following oral administration
  • Gastrointestinal stenosis and intestinal obstruction — possibly due to co-existing pathology or inadequate dilution of the resin
  • Gastrointestinal ischaemia, ischaemic colitis, gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation — sometimes fatal
  • Acute bronchitis and/or broncho-pneumonia associated with inhalation of particles of calcium polystyrene sulfonate

Monitoring

  • Serum potassium — the dosage is a guide only and precise requirements should be decided on the basis of regular serum electrolyte determinations; STOP the resin when the serum potassium falls to 5 mmol/litre. Adequate clinical and biochemical control is essential, especially in patients on digitalis, because of the possibility of severe potassium depletion
  • Serum calcium — 'Serum calcium levels should be estimated at weekly intervals to detect the early development of hypercalcaemia, and the dose of resin adjusted to levels at which hypercalcaemia and hypokalaemia are prevented' (§4.4)
  • All applicable electrolytes — the resin is not totally selective for potassium; hypomagnesaemia and/or hypercalcaemia may occur, so patients should be monitored for all applicable electrolyte disturbances
  • Bowel function and abdominal symptoms — seek prompt review for severe abdominal pain, nausea and vomiting, stomach distension or rectal bleeding; discontinue for clinically significant constipation until normal bowel movement resumes

Clinical monograph

How it works

In the gut the resin exchanges calcium ions for potassium ions, which are then bound to the resin and eliminated in the faeces, lowering total body potassium.

Prescribing in practice

  • Avoid in obstruction or reduced gut motility and do not give with sorbitol, as the combination has been associated with intestinal necrosis; it is not appropriate for life-threatening hyperkalaemia, which needs emergency treatment.
  • It releases calcium and so can cause hypercalcaemia; the calcium form is often preferred over the sodium form where sodium load must be limited.
  • Onset is slow over hours, so it is for ongoing potassium control rather than acute emergencies; separate from other oral medicines to avoid binding them.

Monitoring

Monitor serum potassium and calcium during treatment, stopping or reducing therapy once potassium normalises to avoid hypokalaemia.

Counselling the patient

  • This medicine lowers potassium gradually and is not a treatment for sudden severe high potassium.
  • Report constipation, severe abdominal pain or vomiting promptly.
  • Take it separated from your other tablets to keep them working.

Evidence & guidelines

MHRA advice warns against co-administration of polystyrene sulfonate resins with sorbitol owing to the risk of gastrointestinal injury, and these resins remain established options for chronic hyperkalaemia.

Reference: UK Renal Association; MHRA Drug Safety Update; NICE TA599; NICE TA623; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.